Bio-Techne TECH reported third-quarter fiscal 2025 adjusted earnings per share (EPS) of 56 cents, which surpassed the Zacks Consensus Estimate by 9.8%. The bottom line improved from the year-ago figure of 48 cents. The quarter's adjustments eliminated the impact of certain one-time items, including …
Mairs & Power, an investment advisor, released the “Mairs & Power Balanced Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The stock market reached a record high in February. However, tariff uncertainty in March led to a …
Participants David Trone; Senior Vice President, Investor Relations; Intapp Inc John Hall; Chairman of the Board, Chief Executive Officer; Intapp Inc David Morton; Chief Financial Officer; Intapp Inc Alexei Gogolev; Analyst; JPMorgan Chase & Co Matthew Kikkert; Analyst; Stifel Financial Corp John Kloecker; Analyst; …
The stock market perked up ahead of the Federal Reserve’s interest-rate decision Wednesday on news that Treasury Secretary Scott Bessent and U.S. Trade Representative Jamieson Greer will meet with Chinese officials to discuss trade. The Nasdaq Composite was up 0.3%. Markets are hopeful that …
The Zacks Mortgage & Related Services industry continues to be hurt by the uncertainty in the mortgage market due to several evolving macroeconomic factors. Given the relatively higher mortgage rates, the origination volume and refinance activity are not expected to witness significant growth. Amid …
We recently published an article titled Jim Cramer Says AI Is Back & Discusses These 10 Stocks.In this article, we are going to take a look at where ServiceNow, Inc. (NYSE:NOW) stands against the other stocks. In a recent appearance on CNBC's Squawk on …
Star Jones, award winning television personality & women's heart health advocate, helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign GALWAY, Ireland, May 7, 2025 /PRNewswire/ -- A new Medtronic-sponsored survey of women ages 30-50 reveals …
Truist analyst Joon Lee lowered the firm’s price target on Corcept Therapeutics (CORT) to $135 from $150 and keeps a Buy rating on the shares. The company’s Q1 Korlym revenue of $157.2M was softer than expected due to bandwidth issues with the pharmacy vendor, …
Truist lowered the firm’s price targeton On Semi (ON) to $43 from $52 and keeps a Hold rating on the shares. The company beat on revenue and earnings in both Q1 results and Q2 guide, but the more nuanced story is that the beat …
Needham lowered the firm’s price target on Navitas Semiconductor (NVTS) to $3 from $4 and keeps a Buy rating on the shares. The company posted a solid report and guide, but ongoing tariff volatility and a delayed solar BDS opportunity are pushing out the …